Should I invest in Fractyl?

Valuation metrics show that Fractyl Health, Inc. may be overvalued . Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of GUTS, demonstrate its potential to underperform the market.

What does Fractyl Health do?

Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D . Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century.

Will Fractyl Health stock go up?

Based on short-term price targets offered by two analysts, the average price target for Fractyl Health, Inc. comes to $22.00. The forecasts range from a low of $18.00 to a high of $26.00. The average price target represents an increase of 308.92% from the last closing price of $5.38 .

Is Fractyl Health a buy or sell stock?

The Fractyl Health, Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock . Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.

Fractyl Health Says Potential Diabetes, Obesity Treatment Performed Well in Preclinical Trial (2024)

FRACTYL HEALTH, INC.

Add to a list

To use this feature you must be a member

Log inSign up

Equities

GUTS

US35168W1036

Real-time Estimate Cboe BZX Other stock markets 10:46:19 2024-06-24 am EDT			5-day change	1st Jan Change
4.225 ^USD	-6.32%		-23.25%	0.00%

Jun. 23	Fractyl Health, Inc. Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy at the American Diabetes Association?s 84th Scientific Sessions	CI
May. 20	Fractyl Health, Inc. Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva At Digestive Disease Week 2024	CI

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Fractyl Health, Inc.

Fractyl Health, Inc. Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy at the American Diabetes Association?s 84th Scientific Sessions	Jun. 23	CI
Fractyl Health, Inc. Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva At Digestive Disease Week 2024	May. 20	CI
Earnings Flash (GUTS) FRACTYL HEALTH Reports Q1 Revenue $33,000	May. 13	MT
Fractyl Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Fractyl Health Says New Revita Data Show Sustained Weight Loss, Glucose Control in Type 2 Diabetes	May. 13	MT
Fractyl Health Presents Clinical Update on Revita German Real-World Registry for Patients With Advanced Type 2 Diabetes	May. 13	CI
Fractyl Health Names Adrian Kimber Chief Commercial Officer; Shares Down	Apr. 02	MT
Fractyl Health, Inc. Announces Appointment of Adrian Kimber as Chief Commercial Officer	Apr. 02	CI
Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures	Apr. 01	MT
Rising Rate Cut Hopes Buoy Exchange-Traded Funds, Equity Futures Pre-Bell Monday	Apr. 01	MT
Top Premarket Decliners	Apr. 01	MT
Fractyl Health Shares Drop After Wider 4Q Loss	Apr. 01	DJ
Earnings Flash (GUTS) FRACTYL HEALTH Posts Q4 Revenue $7,000	Apr. 01	MT
Fractyl Health, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 01	CI
Fractyl Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Fractyl Health Shares Rise 40% After FDA Approval of IDE for Revita	Apr. 01	DJ
Fractyl Health, Inc. Receives FDA IDE Approval for the Revita®? Remain-1 Pivotal Study of Weight Maintenance in Obesity After Discontinuation of GLP-1 Based Drugs	Apr. 01	CI
	Mar. 17	CI
Fractyl Health Reports 'Promising' Preclinical Findings From Rejuva Platform; Shares Fall	Mar. 12	MT
Fractyl Health Announces New Results from Its Rejuva® Platform Demonstrating Potent and Durable Effects of A Single Dose of A Human Glp-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the Db/Db Mouse Model of Diabetes and Obesity	Mar. 12	CI
Evercore ISI Initiates Fractyl Health at Outperform Rating	Feb. 28	MT
BofA Securities Initiates Fractyl Health at Buy Rating With $26 Price Target	Feb. 27	MT
Morgan Stanley Initiates Fractyl Health at Overweight Rating With $18 Price Target	Feb. 27	MT
Fractyl Health Appoints Samuel Conaway to its Board of Directors	Feb. 20	CI
Fractyl Health Insider Bought Shares Worth $4,999,995, According to a Recent SEC Filing	Feb. 08	MT

Chart Fractyl Health, Inc.

Duration

Period

Company Profile

Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on approaches to the treatment of metabolic diseases, including type 2 diabetes (T2D) and obesity. The Revita DMR System (Revita), the Companyâs lead product candidate, is an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The Revita system is designed to enable durable and repeatable metabolic improvement via hydrothermal ablation of the dysfunctional duodenal mucosa to address duodenal pathology and consequent metabolic disease progression directly. The Company is involved in enrolling is pivotal Revitalize-1 study in patients with inadequately controlled T2D. It is also developing Rejuva, a locally administered, adeno-associated virus (AAV), delivered pancreatic gene therapy (PGTx), platform. Rejuva is designed to enable long-term remission of T2D and obesity.

Sector

Calendar

07:00am - American Diabetes Association Scientific Symposium - Key Opinion Leader

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.51USD

Average target price

22USD

Spread / Average Target

+387.80%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
FRACTYL HEALTH, INC.	0.00%	216M
VERTEX PHARMACEUTICALS INCORPORATED	+15.34%	121B
REGENERON PHARMACEUTICALS, INC.	+21.01%	114B
ARGENX SE	+16.94%	23.61B
BIONTECH SE	-18.88%	20.43B
GENMAB A/S	-15.96%	16.55B
BEIGENE, LTD.	-11.31%	16.45B
WUXI APPTEC CO., LTD.	-44.35%	15.59B
SAREPTA THERAPEUTICS, INC.	+71.75%	15.19B
NEUROCRINE BIOSCIENCES, INC.	+2.43%	13.54B

Bio Therapeutic Drugs

Stock Market
Equities
GUTS Stock
News Fractyl Health, Inc.
Fractyl Health Says Potential Diabetes, Obesity Treatment Performed Well in Preclinical Trial

Secure and Increase the Performance of your Investments with our Team of Experts at your Side Securing my Investments

"); InvestingChannelQueue.push(function() { aICTags["oop"] = ic_page.defineOutOfPageTag("4Traders/quotepages","zppOOP"); aICTags["oop"].setKval({"adslot":"d_OOP_1"}); aICTags["oop"].render(); }); while (aAdsQueue.length) { (aAdsQueue.shift())(); } InvestingChannelQueue.push(function() { displayViewableAds('InvestingChannel'); $( window ).scroll(function() { displayViewableAds('InvestingChannel'); }); }); }gaEvent('adspv', 'InvestingChannel', 'US');googletag.cmd.push(function() { googletag.pubads().setTargeting('Edition', 'en_US');googletag.pubads().setTargeting('UserType', 'free');googletag.pubads().setTargeting('Content', 'equities');googletag.pubads().setTargeting('codezb', '165185650');googletag.enableServices();googletag.pubads().collapseEmptyDivs();try{googletag.pubads().getSlots().forEach(function(slot){if(slot.getSlotElementId().startsWith('zpp')){;}else{googletag.pubads().refresh([slot],{changeCorrelator: false});}})}catch(error){console.error(error)}});$(document).ready(function() { $( document).on('zbv_visible',function () {startAdsService();}); if (document[zbv_hidden]===false) { startAdsService(); } });